Glenmark FY25 Results: PAT Jumps 16.4% YoY & Revenue Up 12.8%

Glenmark Pharmaceuticals Limited reported its consolidated financial results for the fourth quarter of FY25.

Post the announcement, on May 26, 2025, Glenmark share price opened at ₹1,370.00, down from its previous close of ₹1,420.20. At 9:55 AM, the share price of Glenmark was trading at ₹1,410.90, down by 0.65% on the NSE.

Q4 FY25 Financial Highlights

Revenue for the quarter stood at ₹32,562 million, registering a 6.3% year-on-year (YoY) growth compared to ₹30,630 million in Q4 FY24.

EBITDA came in at ₹5,607 million, an 11.2% increase from ₹5,043 million in the previous corresponding quarter, with the EBITDA margin at 17.2%.

The adjusted Profit After Tax (PAT) for the quarter reached ₹3,466 million, reflecting an adjusted PAT margin of 10.6%.

Full-Year Financial Performance (FY25)

For the fiscal year ended March 31, 2025, Glenmark delivered a robust 12.8% YoY revenue growth, with consolidated revenue of ₹1,33,217 million, up from ₹1,18,131 million in FY24.

The company's EBITDA more than doubled to ₹23,510 million, up from ₹11,953 million, marking significant operational efficiency gains. EBITDA margin for the year stood at 17.6%, highlighting improved profitability.

Glenmark’s adjusted PAT for FY25 came in at ₹13,894 million, with a 10.4% adjusted PAT margin, reflecting continued focus on bottom-line growth.

Geographical Performance Breakdown (Q4 FY25)

• India: Sales from the formulation business reached ₹9,430 million, marking a marginal 0.4% YoY growth.
• North America: Revenue declined by 5.4% YoY to ₹7,146 million due to pricing pressure and market dynamics.
• RoW (Asia, MEA, LATAM, and RCIS): Revenue grew by 5% YoY to ₹7,898 million, indicating a stable market presence.
• Europe: Performance was particularly strong, with revenue increasing 20% YoY to ₹7,335 million.

Management Commentary

Commenting on the results, Glenn Saldanha, Chairman & Managing Director, Glenmark Pharmaceuticals Ltd said, “Our performance reflects the underlying resilience of our business, the strength of our diversified portfolio, and the focused execution of our strategic priorities. The Europe business has shown strong growth, and our branded businesses have delivered sustained results, supported by market expansion and a sharp therapeutic focus. As we move into FY26, we remain committed to building this momentum as we strengthen our global footprint.”

He further added, “We are also proud to share that our innovation-led pipeline continues to gain momentum, with Ichnos Glenmark Innovation (IGI) receiving US FDA Fast Track designation for ISB 2001 — a significant milestone in our journey towards advancing cutting-edge biologics for cancer care. This recognition marks a critical step forward in our aspiration to bring transformative therapies to patients and reinforces our commitment to being a science-led, future-ready organization.”

Also Read: Glenmark Pharma US Unit Introduces Generic Vancomycin Injection in the US Market!

Conclusion

Glenmark Pharmaceuticals ended FY25 on a positive note, delivering growth in revenue, EBITDA, and PAT. The company demonstrated operational execution and margin expansion despite mixed regional performance.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.